Gockley A, Melamed A, Cronin A, et al. - At National Cancer Institute-designated cancer centers, women with platinum-sensitive recurrent ovarian cancer treated who receive secondary surgery vs chemotherapy were assessed for their overall survival. In this retrospective cohort study, researchers included 626 women from 6 National Cancer Institute–designated cancer centers; of these, 146 (23%) received secondary surgery and 480 (77%) received chemotherapy. Secondary surgery was undertaken in patients who were younger and had an earlier-stage disease at diagnosis compared with those receiving chemotherapy. Findings thereby suggest favorable surgical characteristics and a higher likelihood to have minimal residual disease following secondary surgery among patients with platinum-sensitive recurrent ovarian cancer who received secondary surgery. Median overall survival was superior among these patients vs those who received chemotherapy, although unmeasured confounders may explain this observed difference.